Xvivo Perfusion Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Xvivo Perfusion şirketinin toplam hissedar öz sermayesi SEK2.1B ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK2.3B ve SEK195.0M dir. Xvivo Perfusion 'in FAVÖK'ü SEK58.0M faiz karşılama oranı -0.8 dur. Şirketin SEK450.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	-0.8x
Nakit	SEK 449.98m
Eşitlik	SEK 2.08b
Toplam yükümlülükler	SEK 195.02m
Toplam varlıklar	SEK 2.28b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 04

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 27

With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Oct 25

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: XVIVO 'nin kısa vadeli varlıkları ( SEK828.1M ) kısa vadeli yükümlülüklerini ( SEK150.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: XVIVO şirketinin kısa vadeli varlıkları ( SEK828.1M ) uzun vadeli yükümlülüklerini ( SEK44.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: XVIVO borçsuzdur.

Borcun Azaltılması: XVIVO şirketinin 5 yıl önce borç/öz sermaye oranı 1.1% iken borcu yok.

Borç Kapsamı: XVIVO un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: XVIVO şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Xvivo Perfusion Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

New major risk - Earnings quality

With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Consensus EPS estimates increase by 19%

Price target increased by 16% to kr509

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.1% to kr450

Consensus EPS estimates increase by 10%

Now 20% undervalued

Independent Director recently bought kr222k worth of stock

Consensus EPS estimates increase by 27%

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

Consensus EPS estimates increase by 16%

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Consensus EPS estimates increase by 17%, revenue downgraded

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Chairman of the Board recently bought kr281k worth of stock

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter 2023 earnings released: EPS: kr0.076 (vs kr0.18 in 3Q 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Price target increased by 7.9% to kr407

Consensus EPS estimates fall by 13%

Price target increased by 8.0% to kr407

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ) Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published

Consensus EPS estimates fall by 24%

Xvivo Perfusion AB (publ) Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Now 24% undervalued

New minor risk - Shareholder dilution

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Consensus EPS estimates increase by 42%

US Food & Drug Administration Grants Xvivo Perfusion AB (publ) Approval to Include DCD Heartarts in IDE Clinical Trial

Consensus EPS estimates fall by 33%

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated

Consensus EPS estimates fall by 12%

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology

Consensus revenue estimates increase by 10%

Independent Director recently bought kr107k worth of stock

Consensus EPS estimates fall by 30%

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Now 22% undervalued

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Now 21% undervalued

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

Consensus EPS estimates fall by 12%

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

XXvivo Perfusion AB (publ) Appoints Lena Hagman to Chief Operating Officer, COO

Consensus EPS estimates increase by 14%

Xvivo Perfusion AB (Publ) Presents Positive Results from the Australian & New Zealand Heart Preservation Study

Consensus EPS estimates increase by 14%

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Chairman of the Board recently bought kr201k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces CEO Changes

XVIVO Perfusion AB Receives Breakthrough Device Designation Grant from the FDA for the Liver Assist Device

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Xvivo Perfusion AB (publ) (OM:XVIVO) signed an agreement to acquire Machine and perfusion business from Avionord Srl for €12 million.